Menopause is associated with unfavorable metabolic changes that may contribute to the development of metabolic dysfunction-associated steatotic liver disease (MASLD), chronic kidney disease (CKD), and increased cardiometabolic risk. Within the evolving cardiovascular-kidney-metabolic (CKM) framework, MASLD is increasin...
Mohamad Jamalinia, A. Lonardo, Ralf Weiskirchen· Advances in Therapy· 0 citations
The therapeutic landscape for obesity is changing rapidly, driven by the recognition of obesity as a chronic, biologically heterogeneous disease, with clinically relevant organ consequences. In this context, the phase 3 SYNCHRONIZE™-1 trial of survodutide, a once-weekly dual agonist of glucagon receptor and glucagon-li...
A. Lonardo, Ralf Weiskirchen· Exploration of Drug Science· 0 citations
Multiorgan fibrosis is a complex, maladaptive response to chronic injury, where the extracellular matrix (ECM) shifts from serving merely as a structural framework to becoming an active, sustained contributor to disease progression. We propose a unifying mechanobiological framework in which chronic injury promotes fibr...
A. Lonardo, Ralf Weiskirchen· Journal of cell communicatio...· 0 citations
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic disorder shaped by interorgan crosstalk: dynamic, bidirectional communication through which the liver and endocrine organs, gut, adipose tissue, brain, kidney, skeletal muscle, bone, and heart exchange signals to coordinate metabolism, immun...
A. Lonardo, Ralf Weiskirchen· Biomedicines· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
